Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity.

Fajardo G, Bernstein D.

J Am Coll Cardiol. 2007 Aug 7;50(6):537-9. Epub 2007 Jul 23. No abstract available.

2.

Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.

Mukhopadhyay P, Bátkai S, Rajesh M, Czifra N, Harvey-White J, Haskó G, Zsengeller Z, Gerard NP, Liaudet L, Kunos G, Pacher P.

J Am Coll Cardiol. 2007 Aug 7;50(6):528-36. Epub 2007 Jul 23.

3.

[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].

Ducobu J, Sternon J.

J Pharm Belg. 2005;60(3):89-91. Review. French.

PMID:
16252510
4.

CB1 cannabinoid receptor inhibition: promising approach for heart failure?

Mukhopadhyay P, Mohanraj R, Bátkai S, Pacher P.

Congest Heart Fail. 2008 Nov-Dec;14(6):330-4. doi: 10.1111/j.1751-7133.2008.00016.x. Review. No abstract available.

5.

[Endocannabinoid and endocannabinoid receptor antagonists].

Heinzl S.

Med Monatsschr Pharm. 2005 Feb;28(2):40-3. Review. German. No abstract available.

PMID:
15727333
6.

Endocannabinoid control of food intake and energy balance.

Di Marzo V, Matias I.

Nat Neurosci. 2005 May;8(5):585-9. Review.

PMID:
15856067
7.

The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.

Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB.

J Clin Pharm Ther. 2007 Jun;32(3):209-31. Review.

PMID:
17489873
8.

Endocannabinoid system and cardiometabolic risk.

Saavedra LE.

Clin Pharmacol Ther. 2007 Nov;82(5):591-4. Epub 2007 Sep 26. Review.

PMID:
17898706
9.

[Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].

Bramlage P, Böcking W, Kirch W.

Dtsch Med Wochenschr. 2005 Mar 24;130(12):665-8. German.

PMID:
15776349
10.

Drug addiction.

Justinova Z, Panlilio LV, Goldberg SR.

Curr Top Behav Neurosci. 2009;1:309-46. doi: 10.1007/978-3-540-88955-7_13. Review.

11.

Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?

Patti ME.

J Clin Invest. 2010 Aug;120(8):2646-8. doi: 10.1172/JCI44099. Epub 2010 Jul 26.

12.

CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus.

Béquet F, Uzabiaga F, Desbazeille M, Ludwiczak P, Maftouh M, Picard C, Scatton B, Le Fur G.

Eur J Neurosci. 2007 Dec;26(12):3458-64. Epub 2007 Dec 4.

PMID:
18052990
13.

The endocannabinoid system as a novel approach for managing obesity.

Lillo JL.

J Am Osteopath Assoc. 2007 Apr;107(4 Suppl 2):S12-20. Review.

PMID:
17784530
14.

The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.

Sander GE, Giles TD.

Am J Geriatr Cardiol. 2006 Jul-Aug;15(4):255-9. Review. No abstract available.

PMID:
16849895
15.

Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.

Mach F, Montecucco F, Steffens S.

Pharmacol Rep. 2009 Jan-Feb;61(1):13-21. Review.

16.

Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.

Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A.

Eur J Neurosci. 2003 Sep;18(6):1607-14.

17.

Endocannabinoid system and fear conditioning.

Resstel LB, Moreira FA, Guimarães FS.

Vitam Horm. 2009;81:421-40. doi: 10.1016/S0083-6729(09)81016-9. Review.

PMID:
19647121
18.

Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.

Pertwee RG.

Life Sci. 2005 Feb 4;76(12):1307-24. Epub 2004 Dec 8. Review.

PMID:
15670612
19.

2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts.

Wagner JA, Abesser M, Harvey-White J, Ertl G.

J Cardiovasc Pharmacol. 2006 May;47(5):650-5.

PMID:
16775503
20.

Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

Ward SJ, Raffa RB.

Obesity (Silver Spring). 2011 Jul;19(7):1325-34. doi: 10.1038/oby.2011.69. Epub 2011 Apr 7. Review. No abstract available.

Supplemental Content

Support Center